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PURPOSE: To analyze the effect of maintenance hemodialysis on left ventricular diastolic function in patients with
end-stage renal disease.
METHODS: Study population consisted of 42 patients with end-stage renal disease. Before an arteriovenous fistula
was surgically created, the patients were evaluated by conventional and Doppler echocardiography and Doppler
tissue imaging. Then, the patients undergoing hemodialysis treatment when the arteriovenous fistula was
compleated. After the first hemodialysis session (mean 76.14 ¡ 11.37 days) the second echocardiographic
evaluations were performed.
RESULTS: Mean age was 58 ¡ 13 years and 21 (%50) of the patients were female. After maintenance hemodialysis
treatment; peak early (E) and peak late (A) diastolic mitral inflow velocities and E/A ratio were not significantly
change however the deceleration time of E wave and left atrial diameter were significantly increased. Also there
was no change in the early (Em) and late (Am) diastolic myocardial velocities and Em/Am ratios of lateral and septal
walls of left ventricular. E/Em ratio was decreased insignificantly. Pulmonary vein velocities and right ventricular
functions are remained almost unchanged after hemodialysis treatment.
DISCUSSION: The acute and long-term effect of hemodialysis on left ventricular diastolic function is unclearly.
Patients with end-stage renal disease treatment with hemodialysis via arteriovenous fistula experience a variety of
hemodynamic and metabolic abnormalities that predispose to alterations in left and right ventricular functions. The
present study showed that left ventricular diastolic function except left atrial diameter and right ventricular
functions were not significantly change, however left ventricular systolic functions were impaired after
maintenance hemodialysis treatment in patients with end-stage renal disease.
CONCLUSION: It has been suggested that echocardiographic parameters are useful markers for evaluation of left
ventricular and right ventricular functions in patients with end-stage renal disease. However, in patients with end-
stage renal disease treated with hemodialysis, repeated assessment of echocardiographic examinations to observe
serial changes in left and right ventricular functions are not yet well established. In this study, we showed that acute
changes of volume status and electrolytes and autonomic regulation by hemodialysis session did not affect left
ventricular diastolic and right ventricular functions in a relatively long term.
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INTRODUCTION
Cardiovascular complications are the most important
cause of death in patients with end stage renal disease
(ESRD) on hemodialysis treatment.
1,2 Left ventricular
hypertrophy (LVH) and left ventricular (LV) systolic and
diastolic dysfunction are the most common cardiovascular
abnormalities and associated with increased morbidity and
mortality in patients with ESRD.
3 These cardiac abnormal-
ities may result from a variety of mechanisms including
uremia, fluid retention, chronic volume overload, pressure
overload, renal anemia, high-flow arteriovenous shunting,
and hyperparathyroidism.
3-5 The effects of hemodialysis
(HD), peritoneal dialysis and arteriovenous fistula (AVF) to
the cardiac abnormalities are not clear yet.
6,7
Arteriovenous fistula, which was used for vascular access
in patients with ESRD, increases stroke volume load on the
left ventricle and this may contributes to LVH and may
results in LV systolic and diastolic dysfunction with time.
8
Also the presence of an AVF reduces systemic vascular
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9 Studies after AVF closure because of complica-
tions suggest that AVF may leads to progression of LVH
and high cardiac output.
10
Numerous echocardiographic techniques can be used to
evaluate LV diastolic function. LV diastolic filling is
analyzed from recordings of mitral inflow Doppler velo-
cities. The velocity of the septal and lateral myocard, which
has been shown to reflect the rate of myocardial relaxation,
can be recorded with tissue Doppler imaging (DTI).
Pulmonary vein flow velocities contribution to recognize
diastolic dysfunction. Also the left atrial (LA) diameter and
volume reflect the burden of LV diastolic filling.
11,12
However, the pathophysiology of LV diastolic dysfunc-
tion and the contribution of AVF and hemodialysis to LV
diastolic function remain unclearly in patients with ESRD.
We aimed to investigate the effect of maintenance HD
treatment on LV systolic and diastolic function in patients
with ESRD.
PATIENTS AND METHOD
Patient Population
The prospective study was performed between January
2007 and February 2008 in Erciyes Univercity Medical
Faculty Hospital. Study population consisted of 42 patients
with ESRD. Before an AVF was surgically created for HD,
the patients were evaluated by conventional and Doppler
echocardiography. Then, an AVF was surgically created in
the patients, who started HD via AVF when the AVF was
compleated. After the first HD session (mean 76.14 ¡ 11.37
days) the second echocardiographic evaluations were
performed. The patients were dialyzed via AVF three times
a week for four hours. The second evaluations were
performed 6-8 hours after the last HD session to avoid
from acute volume loading. LV systolic and diastolic
function parameters were obtained. The local ethics com-
mittee approved the study, and informed consent was
obtained for each patient.
The patients, who had new diagnosis ESRD and planned
HD via AVF, sinus rhythm, LV ejection fraction (EF) above
50%, no history of myocardial infarction, and no evidence of
valvular disease included to the study. The patients with
cerebral vascular disease, clinical and electrocardiographic
evidences of myocardial ischemia, history of coronary artery
disease, pericardial disease, heart failure (EF,50%), valvu-
lar heart disease and chronic pulmoner disease were
excluded from the study. The patients had no signs or
symptoms of heart failure at any time in the study.
Clinical and laboratory data were obtained from the
patients on the day of echocardiographic examination
before creation of AVF. These examinations were repeated
after beginning of the HD session.
Echocardiographic evaluations
Echocardiographic studies were performed by the same
cardiologist (MD) over three cardiac cycles before and after
creation of AVF by Vivid 7 Dimension (General Electric
Healthcare Company, Milwaukee, WI, USA) with a 3 MHz
transducer in the left lateral position. Analysis was
performed according to the guidelines of the American
Society of Echocardiography recommendations.
13
Left ventricular end-diastolic diameter (LVEDD), left
ventricular end-systolic diameter (LVESD) and septal-
posterior wall thicknesses were measured by M-mode in
the parasternal long-axis view and EF was calculated
according to the Teicholz formula via these measure-
ments.
14 To evaluation of diastolic properties of the left
ventricle, the mitral inflow velocities and Doppler tissue
imaging (DTI) were evaluated from the apical four-chamber
view. Pulmonary vein flow velocities were obtained from
the right posterior pulmonary vein in the apical view. The
LA diamater was measured in the parasternal long-axis
view.
15
Diastolic filling is classified on the basis of the peak early
(E) and late (A) diastolic mitral inflow velocities, E/A ratio,
E wave deceleration time (DT) and isovolemic relaxation
time (IVRT). Also pulmonary vein flow velocities: systolic
velocity (PVS), diastolic velocity (PVd) and atrial flow
reversal velocity (PVa) were recorded. The early diastolic
myocardial velocity (Em) and late diastolic myocardial
velocity (Am) were recorded from midsegment of the lateral
and septal myocardial walls with DTI.
12,13 Septal Em value
was used to measure E/Em ratio. Right ventricle early (E)
and late (A) ventricular inflow velocities were measured by
pulsed wave Doppler placing the sample volume in
between the tips of the tricuspid valve in the apical four
chamber window.
End-diastolic left ventricular septal and posterior wall
thicknesses (IVSEDD, PWEDD) and internal dimensions
were used to calculate left ventricular mass by using the
following equation: left ventricular mass = 1.04 60.8 [(left
ventricular wall thicknesses + internal dimension) – (inter-
nal dimension)] + 0.6 g. Left ventricular hypertrophy was
defined as left ventricular mass index (LVMI), which was
calculated with left ventricular mass in grams divided by
body surface area in square meters, higher than 116.0 for
men and 104.0 for women.
16
Statistical Analysis
SPSS 15.0 statistic software was used for the statistical
analysis. The Kolmogorov-Smirnov test was used to deter-
mine normality of distributions of variables. Continuous
variables with normal distribution were presented as mean
¡ standard deviation. Median value was used in variables
without normal distribution. The qualitative variables were
given as percent and the correlation between categorical
variables was investigated by the x
2 test. To compare
variables before an AVF creation and after an AVF creation,
paired t test (for the parametric variables), Wilcoxon test (for
the nonparametric variables), and McNemar test (for
categorized variables) were performed. The correlation
analysis was evaluated by the Pearson’s correlation test
for parametric variables and by Spearman’s correlation test
for nonparametric variables. P value of ,0.05 was con-
sidered to be significant.
RESULTS
Demographic and clinical characteristics of the patients
with ESRD are shown in Table 1. Mean age was 58 ¡ 13
years and 21 (%50) of the patients were female. The most
known causes of ESRD were diabetes mellitus and hyper-
tension, respectively. Twenty-eight of the 42 patients with
ESRD were taking anti-hypertensive treatment before AVF.
These anti-hypertensive agents were not modifieted or
interrupted and shown in Table 1.
Comparison of biochemical and clinical findings between
before and after HD treatment are shown in Table 2. Levels
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980of serum hemoglobin, triglyceride, albumin, calcium, and
alkaline phosphatase were significantly increased after
maintenance HD treatment compared to baseline values.
However, levels of low density lipoprotein, blood urea
nitrogen, uric acid, and phosphorus and calcium x
phosphorus product were significantly decreased after
creation of AVF and HD treatment compared to baseline
values. There was no significant difference with regard to
other parameters including white blood cell count, total
cholesterol, high density lipoprotein, serum creatinine,
glucose, parathyroid hormone, C-reactive protein, body
mass index, blood pressure of diastolic and systolic between
before and after maintenance HD treatment.
The baseline echocardiographic measurements and the
changes in these parameters after maintenance HD treat-
ment are presented in Table 3. In the comparison of
echocardiographic findings; LVEDD, LVESD, IVSEDD,
PWEDD, LA diameter, LVM, LVMI, and presence of LVH
were significantly increased, however, EF value was
significantly decreased after creation of AVF and HD
treatment compared to baseline value.
Table 4 shows comparisons of conventional Doppler
echocardiography and DTI findings. In our study, E wave
DT was significantly increased after HD treatment com-
pared to baseline value. There was no significant difference
with regard to other mitral inflow velocities including E
value, A value, E/A ratio, and IVRT. Parameters of DTI
such as values of septal and lateral wall Em, Am and Em/
Am ratio were not significantly change. There was no
significant difference with pulmonary vein flow velocities;
PVS, PVd, PVS/d ratio, and PVAr between before and after
maintenance HD treatment.
Table 1 - Demographic and clinical characteristics of
patients with end-stage renal disease (n: 42).
Age (year) 58 ¡ 13
Gender
Female 21 (50%)
Male 21 (50%)
The cause of end-stage renal disease
Diabetes mellitus 14 (33.3%)
Hypertension 8 (19%)
Glomerulonephritis 3 (7.2%)
Obstructive uropathy 4 (9.6%)
Amyloidosis 3 (7.2%)
Polycystic kidney disease 1 (2.3%)
Unknown 9 (21.4%)
Presence of diabetes mellitus 15 (35%)
Presence of hypertension 28 (66%)
Smoking 10 (23%)
Body mass index (kg/m
2) 27.3 ¡ 5.0
Diastolic blood pressure (mm Hg) 83 (60-90)
Systolic blood pressure (mm Hg) 135(90-150)
Medications for hypertension (n)
Calcium antagonists 21
Beta blockers 6
ACE inhibitors 3
Angiotensin-II receptor blockers 4
Table 2 - Comparison of laboratory and clinical findings
of the patients before and after creation of AVF.
Parameter Before AVF After AVF p
White blood cell count (mm
3) 7.9 ¡ 3.4 7.4 ¡ 2.6 0.351
Hemoglobin (g/dL) 9.8 ¡ 1.4 11.2 ¡ 1.3 0.001
Total cholesterol (mg/dL) 172.1 ¡ 40.9 165.8 ¡ 44.3 0.307
HDL (mg/dL) 31.5 ¡ 9.7 32.6 ¡ 12.3 0.553
LDL (mg/dL) 112.4 ¡ 29.5 99.2 ¡ 31.2 0.012
Triglyceride (mg/dL) 139.8 ¡ 78.3 170.8 ¡ 79.6 0.008
Blood urea nitrogen (mg/dL) 72.3 ¡ 32.4 50.3 ¡ 24.5 0.001
Creatinine (mg/dL) 7.1 ¡ 3.9 6.1 ¡ 3.3 0.050
Uric acid (mg/dL) 7.4 ¡ 1.9 6.2 ¡ 1.7 0.001
Albumin (g/dL) 2.9 ¡ 0.7 3.3 ¡ 0.6 0.003
Calcium (mg/dL) 8.1 ¡ 0.8 8.8 ¡ 0.6 0.003
Phosphorus (mg/dL) 5.4 ¡ 1.7 4.3 ¡ 1.4 0.001
Calcium6phosphorus (mg
2/dL
2) 48.7 ¡ 13.7 41.6 ¡ 12.9 0.004
Glucose (mg/dL) 107(46-264) 102(73-456) 0.218
Alkaline phosphatase (IU/L) 83(40–308) 94(44-585) 0.059
Parathyroid hormone (pg/mL) 185(6-1289) 138(22-1014) 0.383
C-reactive protein (mg/dL) 10(3-148) 8(3-110) 0.737
Body mass index (kg/m
2) 27.3 ¡ 5.0 27.2 ¡ 4.9 0.528
Diastolic BP (mm Hg) 83(60-90) 81(60-95) 0.389
Systolic BP (mmHg) 135(90-150) 131(100-150) 0.574
AVF: arteriovenous fistula, HDL: High density lipoprotein, LDL: Low
density lipoprotein, BP: Blood pressure
Table 3 - Comparison of M-mode echocardiographic
findings of the patients before AVF creation and after
AVF creation.
Parameter Before AVF After AVF p
LV end-diastolic diameter (mm) 49.0 ¡ 4.7 50.6 ¡ 4.6 0.033
LV end-systolic diameter (mm) 33.8 ¡ 4.4 35.9 ¡ 5.1 0.010
LV ejection fraction (%) 59.6 ¡ 5.6 56.9 ¡ 5.8 0.023
IVS end-diastolic diameter (mm) 11.0 ¡ 1.5 11.7 ¡ 1.9 0.013
PW end-diastolic diameter (mm) 10.5 ¡ 1.5 11.4 ¡ 1.8 0.002
Left atrial diameter (mm) 34.9 ¡ 4.0 36.3 ¡ 4.1 0.011
LV mass (g) 200.6 ¡ 56.6 225.6 ¡ 55.0 0.003
LV mass index (g/m
2) 112.3 ¡ 29.2 126.0 ¡ 25.2 0.002
Presence of LV hypertrophy 18 (42%) 30 (71%) 0.003
AVF: arteriovenous fistula, LV: Left ventricular, IVS: Interventricular
septum, PW: Posterior wall
Table 4 - Comparison of Doppler echocardiography and
Doppler tissue imaging findings of the patients before
and after HD treatment.
Before HD After HD p
E (cm/s) 80.2 ¡ 26.6 72.5 ¡ 23.3 0.069
A (cm/s) 82.6 ¡ 26.0 83.2 ¡ 25.8 0.881
E/A ratio 1.0 ¡ 0.4 0.9 ¡ 0.4 0,228
DT (ms) 141.3 ¡ 41.4 162.8 ¡ 40.9 0.002
IVRT (ms) 96.0 ¡ 19.5 97.0 ¡ 19.9 0.816
PVS (cm/s) 58.5 ¡ 12.9 55.3 ¡ 14.1 0.183
PVd (cm/s) 50.8 ¡ 15.0 48.1 ¡ 14.0 0.316
PVS/PVd ratio 1.2 ¡ 0.3 1.1 ¡ 0.3 0,862
PVAr (cm/s) 36.9 ¡ 12.2 38.8 ¡ 10.6 0.359
Lateral Sm (cm/s) 7.7 ¡ 2.6 7.2 ¡ 2.3 0.309
Lateral Em (cm/s) 8.1 ¡ 3.4 8.0 ¡ 2.6 0.806
Lateral Am (cm/s) 10.1 ¡ 3.3 9.3 ¡ 2.9 0.112
Lateral Em/Am ratio 0.8 ¡ 0.4 0.9 ¡ 0.4 0.447
Septal Sm (cm/s) 6.9 ¡ 1.7 6.3 ¡ 1.5 0.05
Septal Em (cm/s) 6.6 ¡ 2.3 6.1 ¡ 1.9 0.237
Septal Am (cm/s) 8.8 ¡ 2.6 8.8 ¡ 2.4 1
Septal Em/Am ratio 0.7 ¡ 0.3 0.7 ¡ 0.4 0.708
E/Em ratio 13.8 ¡ 7.2 12.2 ¡ 4.5 0.114
HD: hemodialysis, E: peak early diastolic mitral inflow velocity, A: peak
late diastolic mitral inflow velocity, DT: deceleration time, IVRT:
isovolemic relaxation time, Sm: systolic myocardial velocity, Em: early
diastolic myocardial velocity, Am: late diastolic myocardial velocity, PVS:
pulmonary vein peak systolic velocity, PVd: pulmonary vein peak diastolic
velocity, PVAr: pulmonary vein peak atrial reversal velocity
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early (E) and late (A) inflow velocities, E/A ratio and RV
free wall myocardial velocities were not significantly change
after maintenance HD treatment.
DISCUSSION
In patients with ESRD, it has been suggested that
echocardiographic parameters are useful markers for pre-
dicting the development of LV dysfunction.
17 However;
serial changes of systolic and diastolic functions in ESRD
patients with time are not yet well established. In the
present study, we have found by conventional and Doppler
echocardiography that LV diastolic function and RV
functions did not significantly change, however LV systolic
function was significantly impaired after starting HD
treatment in patients with ESRD.
Patients with ESRD treatment with HD via AVF experi-
ence a variety of hemodynamic and metabolic abnormalities
that predispose to alterations in LV systolic and diastolic
function parameters. Increasing myocardial calcium level,
lipid peroxides level, oxidative stres and decreasing anti-
oxidants may affect LV myocardial functions and loading
conditions may affect the evaluation of LV functions by
echocardiography.
18,19
The potential acute effect of HD on LV diastolic function
has been addressed in several studies. Previous studies
demonstrated that an improvement or unchanged or dete-
rioration of LV diastolic functions after HD session.
20-22 In
these studies, investigators examined echocardiographic
parameters before and immediately after HD session. The
acute changes of echocardiographic parameters after HD
treatment may be explained by several mechanisms such as
the change of serum ionized calcium concentration, sym-
pathetic hyperactivity, increased oxidative stress during
hemodialysis treatment and disease of smaller resistance
vessels.
21
Chronic effects of HD on LV diastolic function is
unclearly. Studies were reported different results: a sig-
nificant alterations at LV longitudinal myocardial function
parameters assessed by color DTI, improved indices for
left ventricular diastolic function and did not change
Doppler parameters of mitral inflow and pulmonary venous
flow.
23-25 The coexistence of hypervolemia, hypercircula-
tion, LV hypertrophy, and interstitial fibrosis may predis-
pose to LV diastolic dysfunction.
In our study, we evaluate and compare LV functions
before and nearly 2K months after creation of AVF and
starting HD treatment. To avoid the acute effect of HD
treatment, the second echocardiographic evaluations were
performed after 6-8 hours from the last HD session.
Although LV systolic function was significantly impaired,
diastolic function did not significantly change, except LA
diameter, with time after maintenance HD treatment.
Indeed we would expect that hemodialysis and AVF cause
cardiovascular change and had negative effects on LV
systolic and diastolic functions because of methabolic
changes, acute volume changes, sympathetic hyperactivity,
increased oxidative stress and hyperdynamic state.
During ventricular diastole the LA is directly exposed to
LV filling pressure. Therefore, increased LA size and
volume may reflect the duration and severity of diastolic
dysfunction.
26 Effect of HD on LA dimension could be
explained by the factors that influence LV filling. Left
atrium pressure increases and resulting in augmented LA
dimensions whenever preload increases and/or LV com-
pliance decreases. In patients undergoing HD, the LA
parameters reported as a marker of chronic diastolic
dysfunction, however some investigators showed that LA
parameters were similar in the group of healthy volun-
teers.
25,27 Another important observation of our study was
the mean LA dimension was significantly higher after HD
treatment than basaline value. Myocardial velocity by DTI
and LA parameters have been proposed as relatively
preload independent measurements of diastolic function
and more accurately reflects LV diastolic dysfunction.
26,28
In patients with ESRD, because of the renal anemia,
systemic hypertension, volume overload, and the presence
of an AVF with high-flow rates, LV systolic and diastolic
diameters, wall thickness and cardiac output are increased
and indirectly EF is decreased. Several studies have shown
that patients with ESRD before and on dialysis had higher
LV volumes and dimensions.
29,30 Increases in LVEDD,
LVESD, IVSEDD, PWEDD, and LVMI were found after
maintenance HD treatment in our study. Furthermore, in
our study, 2% decrease in ejection fraction was observed
following the HD treatment. Previous studies demonstrated
that either an improvement or unchanged of LV systolic
function after HD.
22,31 McIntyre et al. showed that HD
treatment was associated with significant reductions in
myocardial blood flow. Stress–induced myocardial ische-
mia occurs in the absence of large-vessel epicardial
coronary disease and repetitive episodes of ischemia may
lead to LV systolic dysfunction.
31 After HD treatment,
several factors such as the semi-quantitative assessment of
wall motion and altered loading conditions by HD, limit the
evaluation of LV systolic function by echocardiography
correctly. In our study LV size was only judged by
dimension measures and EF determined by the Teichholz
equation. It may be misleading because of the loading
contidions. Although we reported significant structural
changes in LV systolic function, EF of LV before and after
HD session were within normal values. So we do not
suggest that these findings would be have a biological
impact.
In patients with ESRD, anemia leads to a chronic increase
in cardiac output and contributes to diastolic dysfunction.
32
Also worse diastolic function in patients on dialysis was
associated with increased serum phosphorus and calcium-
phosphorus ion product.
33 In our study, after HD treatment,
Table 5 - Inflow velocities measured from tricuspid valve
and right ventricle free myocardial wall tissue Doppler
velocity changes after maintenance hemodialysis
treatment.
Before HD After HD p
Tricuspid E (m/s) 57.4 ¡ 14.9 54.2 ¡ 12.3 0.209
Tricuspid A (m/s) 54.5 ¡ 15.0 57.1 ¡ 17.9 0.210
Tricuspid E/A ratio 1.1 ¡ 0.4 1.0 ¡ 0.3 0.137
RV free wall
Em 11.7 ¡ 4.6 10.7 ¡ 4.2 0.107
Am 16.8 ¡ 4.3 15.7 ¡ 4.2 0.197
Em/Am ratio 0.7 ¡ 0.4 0.7 ¡ 0.4 0.492
Sm 14.0 ¡ 3.8 12.8 ¡ 4.6 0.084
HD: hemodialysis, E: peak early diastolic tricuspid inflow velocity, A: peak
late diastolic tricuspid inflow velocity, RV; Right Ventricle, Em: early
diastolic myocardial velocity, Am: late diastolic myocardial velocity, Sm:
systolic myocardial velocity
Hemodialysis and ventricular function
Duran M et al.
CLINICS 2010;65(10):979-984
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phorus and calcium-phosphorus ion product were mean-
ingfully decreased.
The pathogenesis of hypertension in ESRD patients is
multifactorial. Hypervolemia has been considered a major
pathogenetic factor and other factors such as a disturbed
hormone profile with an activated renin-angiotensin system,
increased catecholamine, vasopressin, endothelin, and
perhaps decreased nitrous oxide activity seems to play a
role in the high incidence of hypertension in ESRD
patients
34. In our study, the systolic and diastolic blood
pressure in ESRD patients did not significantly change after
maintenance HD treatment. There were twenty-eight
patients, who have hypertension, taking antihypertensive
agents before HD treatment in our group and we did not
change this agents after creation of AVF. Hemodialysis may
change metabolic parameters that affect systolic and
diastolic blood pressure and hemodialysis and AVF may
change volum status in our patients and as a result the
systolic and diastolic blood pressure did not significantly
change.
After creation of an AVF in patients with ESRD, because
of the reduction in peripheral resistance and increase in
sympathetic nervous system activity, stroke volume and
heart rate, there is a 10–20% increase in cardiac output. The
long-term effects of an AVF creation were left ventricular
hypertrophy, high-output cardiac failure, myocardial ische-
mia, and venous stenosis.
35,36However, the effect of AVFs
on cardiac function, remodeling, and long-term mortality
remains unclear. Our study design did not allow separation
of the effects of an AVF and HD procedures.
Arinc et al. showed that RV systolic and diastolic
velocities detected by DTI were not or only minimally
affected by preload reduction in hemodialysis patients.
37
Drighil et al. show that both systolic and diastolic DTI
velocities of the RV are preload dependent.
38 In our study
RV systolic and diastolic functions did not change after
maintenance HD treatment. Although we used echocardio-
graphy to evaluate RV functions, echocardiography is not
the best method to evaluate RV functions, we would not be
able to use other imaging methods and also we did not
evaluate autonomic regulation.
There were some limitations of the present study. Firstly,
we did not evaluate the volume situation of study patients
before and after HD treatment with the objective methods
(like evaluation of weight gain) and it is possible that some
patients on hemodialysis continued to have significant fluid
overload even after HD treatment. Secondly, hemodynamic
changes associated with AVF and HD treatment but in our
study they can not be differentiated. To separate the effect of
HD and AVF, some patients can doing HD with another
way like permanent catheter. The role of AVF should be
investigated in future studies. Thirdly, the results were
based on a small number of patients, and our findings wait
further validation. Forthly, the observation period was not
long enough to explain long term effects but this period is
enough to show relatively long term effects of HD
(compaired to acute changes).
In conclusion, our data indicated that LV diastolic
function and RV systolic and diastolic functions did not
change in patients with ESRD after HD treatment. We
showed that acute changes of volume status and electrolytes
and autonomic regulation by HD session did not affect LV
diastolic functions in a relatively long-term. Also we suggest
that these results would be same if applying chronic renal
failure patients with hypertrophic hearts.
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